National Bank of Canada FI Reduces Stake in Moderna, Inc. (NASDAQ:MRNA)

National Bank of Canada FI trimmed its stake in Moderna, Inc. (NASDAQ:MRNA) by 37.0% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 195,424 shares of the company’s stock after selling 114,956 shares during the quarter. National Bank of Canada FI owned approximately 0.05% of Moderna worth $22,925,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Ogorek Anthony Joseph NY ADV bought a new stake in shares of Moderna in the fourth quarter valued at approximately $27,000. Arlington Trust Co LLC increased its holdings in Moderna by 4,833.3% during the 4th quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock worth $29,000 after acquiring an additional 290 shares during the period. Cedar Wealth Management LLC increased its holdings in Moderna by 45.0% during the 1st quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock worth $31,000 after acquiring an additional 90 shares during the period. Westside Investment Management Inc. bought a new stake in Moderna during the 1st quarter worth approximately $32,000. Finally, Rise Advisors LLC increased its holdings in Moderna by 953.3% during the 1st quarter. Rise Advisors LLC now owns 316 shares of the company’s stock worth $34,000 after acquiring an additional 286 shares during the period. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Moderna Trading Up 3.2 %

Moderna stock traded up $3.76 during trading hours on Thursday, reaching $121.95. The stock had a trading volume of 1,246,625 shares, compared to its average volume of 4,021,267. The stock has a market cap of $46.74 billion, a PE ratio of -7.77 and a beta of 1.66. Moderna, Inc. has a 52 week low of $62.55 and a 52 week high of $170.47. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.03 and a quick ratio of 3.91. The company has a fifty day simple moving average of $135.03 and a 200-day simple moving average of $114.92.

Moderna (NASDAQ:MRNA) last posted its earnings results on Thursday, May 2nd. The company reported ($3.07) EPS for the quarter, topping the consensus estimate of ($3.59) by $0.52. Moderna had a negative net margin of 115.82% and a negative return on equity of 20.10%. The firm had revenue of $167.00 million during the quarter, compared to analysts’ expectations of $93.26 million. During the same period last year, the company posted $0.19 EPS. The company’s quarterly revenue was down 91.0% compared to the same quarter last year. Analysts forecast that Moderna, Inc. will post -7.46 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have commented on MRNA. Jefferies Financial Group reissued a “buy” rating and issued a $125.00 price target on shares of Moderna in a research note on Tuesday, April 9th. Oppenheimer boosted their price target on shares of Moderna from $163.00 to $179.00 and gave the stock an “outperform” rating in a research note on Wednesday, June 12th. Evercore ISI reissued an “in-line” rating and issued a $120.00 price target on shares of Moderna in a research note on Thursday, June 27th. UBS Group boosted their price target on shares of Moderna from $143.00 to $151.00 and gave the stock a “buy” rating in a research note on Tuesday, May 7th. Finally, Piper Sandler reissued an “overweight” rating and issued a $214.00 price target on shares of Moderna in a research note on Thursday, June 27th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $133.88.

Insider Activity at Moderna

In related news, Director Noubar Afeyan sold 15,000 shares of Moderna stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $110.92, for a total transaction of $1,663,800.00. Following the completion of the transaction, the director now directly owns 2,026,931 shares of the company’s stock, valued at approximately $224,827,186.52. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In related news, Director Noubar Afeyan sold 15,000 shares of Moderna stock in a transaction dated Wednesday, May 1st. The shares were sold at an average price of $110.92, for a total transaction of $1,663,800.00. Following the completion of the transaction, the director now directly owns 2,026,931 shares of the company’s stock, valued at approximately $224,827,186.52. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, CFO James M. Mock sold 689 shares of Moderna stock in a transaction dated Monday, July 8th. The shares were sold at an average price of $118.24, for a total transaction of $81,467.36. Following the transaction, the chief financial officer now directly owns 7,269 shares of the company’s stock, valued at $859,486.56. The disclosure for this sale can be found here. Insiders sold a total of 381,239 shares of company stock valued at $53,661,337 in the last three months. Company insiders own 15.70% of the company’s stock.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.